- Home
- TLSA vs CYBN Comparison
TLSA vs CYBN Comparison
Compare TLSA & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- CYBN
- Stock Information
- Founded
- TLSA 2013
- CYBN 2019
- Country
- TLSA United Kingdom
- CYBN Canada
- Employees
- TLSA N/A
- CYBN N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- CYBN Pharmaceuticals and Biotechnology
- Sector
- TLSA Health Care
- CYBN Health Care
- Exchange
- TLSA Nasdaq
- CYBN Nasdaq
- Market Cap
- TLSA 187.0M
- CYBN 176.5M
- IPO Year
- TLSA 2000
- CYBN N/A
- Fundamental
- Price
- TLSA $1.97
- CYBN $6.07
- Analyst Decision
- TLSA
- CYBN Strong Buy
- Analyst Count
- TLSA 0
- CYBN 3
- Target Price
- TLSA N/A
- CYBN $85.00
- AVG Volume (30 Days)
- TLSA 455.3K
- CYBN 673.9K
- Earning Date
- TLSA 05-06-2025
- CYBN 11-12-2025
- Dividend Yield
- TLSA N/A
- CYBN N/A
- EPS Growth
- TLSA N/A
- CYBN N/A
- EPS
- TLSA N/A
- CYBN N/A
- Revenue
- TLSA N/A
- CYBN N/A
- Revenue This Year
- TLSA N/A
- CYBN N/A
- Revenue Next Year
- TLSA N/A
- CYBN N/A
- P/E Ratio
- TLSA N/A
- CYBN N/A
- Revenue Growth
- TLSA N/A
- CYBN N/A
- 52 Week Low
- TLSA $0.63
- CYBN $4.81
- 52 Week High
- TLSA $2.60
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- TLSA 53.23
- CYBN 45.10
- Support Level
- TLSA $1.90
- CYBN $5.72
- Resistance Level
- TLSA $2.18
- CYBN $6.52
- Average True Range (ATR)
- TLSA 0.17
- CYBN 0.30
- MACD
- TLSA 0.02
- CYBN 0.05
- Stochastic Oscillator
- TLSA 46.48
- CYBN 38.48
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.